A review of the management of ductal carcinoma in situ following breast conserving surgery

Breast

Volumn 22, Issue 6, 2013, Pages 1019-1025

  Boxer, M M ^a   Delaney, G P ^a,b,c   Chua, B H ^d,e  

^a Liverpool Cancer Therapy Centre   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Breast conservation; Ductal carcinoma in situ; Endocrine treatment; Radiotherapy

Indexed keywords

TAMOXIFEN;

AGE DISTRIBUTION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DRUG EFFICACY; ENDOMETRIUM CANCER; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; PARTIAL MASTECTOMY; PATIENT SAFETY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; VENOUS THROMBOEMBOLISM;

BREAST CONSERVATION; DUCTAL CARCINOMA IN SITU; ENDOCRINE TREATMENT; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TAMOXIFEN;

EID: 84887146745     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.08.012     Document Type: Review

References (47)

1. Lakhani SR ea. WHO classification of tumours of the breast, 4th ed. (viewed online 8/1/13 at ). http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb4/index.php.
2. Breast Cancer in Australia; an overview October 2013, Australian Institute of Health and Welfare, [accessed January 2013]. http://www.canceraustralia.gov.au/research-data/cancer-data/cancer-reports/breast-cancer-data-reports.
3. Cancer Research UK. [accessed January 2013]. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/.
4. American Cancer Society Cancer Facts & Figures 2012 2012, American Cancer Society, Atlanta, [accessed January 2013]. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
5. Delaney G., Ung O., Cahill S., Bilous M., Boyages J. Ductal carcinoma in situ. Part 2: Treatment. Aust N Z J Surg 1997, 67:157-165.
6. Boyages J., Delaney G., Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999, 85:616-628.
7. Group E.B.C.T.C., Correa C., McGale P., Taylor C., Wang Y., Clarke M., et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010, 2010:162-177.
8. Wapnir I.L., Dignam J.J., Fisher B., Mamounas E.P., Anderson S.J., Julian T.B., et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011, 103:478-488.
9. Solin L.J., Fourquet A., Vicini F.A., Haffty B., Taylor M., McCormick B., et al. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 2001, 91:1090-1097.
10. Cutuli B., Lemanski C., Le Blanc-Onfroy M., de Lafontan B., Cohen-Solal-Le-Nir C., Fondrinier E., et al. Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases. Cancer Radiother 2013, 17:196-201.
11. Warren J.L., Weaver D.L., Bocklage T., Key C.R., Platz C.E., Cronin K.A., et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. Cancer 2005, 104:1840-1848.
12. MacDonald H.R., Silverstein M.J., Mabry H., Moorthy B., Ye W., Epstein M.S., et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 2005, 190:521-525.
13. Bijker N., Meijnen P., Peterse J.L., Bogaerts J., Van Hoorebeeck I., Julien J.P., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24:3381-3387.
14. Cuzick J., Sestak I., Pinder S.E., Ellis I.O., Forsyth S., Bundred N.J., et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011, 12:21-29.
15. Holmberg L., Garmo H., Granstrand B., Ringberg A., Arnesson L.G., Sandelin K., et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008, 26:1247-1252.
16. Goodwin A., Parker S., Ghersi D., Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2009, CD000563.
17. Wong J.S., Kaelin C.M., Troyan S.L., Gadd M.A., Gelman R., Lester S.C., et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006, 24:1031-1036.
18. Hughes L.L., Wang M., Page D.L., Gray R., Solin L.J., Davidson N.E., et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:5319-5324.
19. Rudloff U., Jacks L.M., Goldberg J.I., Wynveen C.A., Brogi E., Patil S., et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 2010, 28:3762-3769.
20. Fisher B., Dignam J., Wolmark N., Wickerham D.L., Fisher E.R., Mamounas E., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000.
21. Allred D.C., Anderson S.J., Paik S., Wickerham D.L., Nagtegaal I.D., Swain S.M., et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 2012, 30:1268-1273.
22. Fisher B. Ductal carcinoma in situ of the breast 2002, Lippincott Williams & Wilkins. 2nd ed. M.J. Silverstein (Ed.).
23. Petrelli F., Barni S. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Radiother Oncol 2011, 100:195-199.
24. Staley H., McCallum I., Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012, 10:CD007847.
25. Bijker N., Peterse J.L., Duchateau L., Julien J.P., Fentiman I.S., Duval C., et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001, 19:2263-2271.
26. Ringberg A., Nordgren H., Thorstensson S., Idvall I., Garmo H., Granstrand B., et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast-results from the Swedish randomised trial. Eur J Cancer 2007, 43:291-298.
27. Pinder S.E., Duggan C., Ellis I.O., Cuzick J., Forbes J.F., Bishop H., et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer 2010, 103:94-100.
28. Silverstein M.J., Lagios M.D., Craig P.H., Waisman J.R., Lewinsky B.S., Colburn W.J., et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996, 77:2267-2274.
29. Silverstein M.J. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003, 186:337-343.
30. Silverstein M.J., Lagios M.D. Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr 2010, 2010:193-196.
31. Sanders M.E., Schuyler P.A., Dupont W.D., Page D.L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005, 103:2481-2484.
32. Wallis M.G., Clements K., Kearins O., Ball G., Macartney J., Lawrence G.M. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 2012, 106:1611-1617.
33. Silverstein M.J., Lagios M.D., Groshen S., Waisman J.R., Lewinsky B.S., Martino S., et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999, 340:1455-1461.
34. Dunne C., Burke J.P., Morrow M., Kell M.R. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009, 27:1615-1620.
35. Wang S.Y., Chu H., Shamliyan T., Jalal H., Kuntz K.M., Kane R.L., et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst 2012, 104:507-516.
36. Rakovitch E., Pignol J.P., Hanna W., Narod S., Spayne J., Nofech-Mozes S., et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol 2007, 25:5591-5596.
37. Bartelink H., Horiot J.C., Poortmans P.M., Struikmans H., Van den Bogaert W., Fourquet A., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265.
38. Omlin A., Amichetti M., Azria D., Cole B.F., Fourneret P., Poortmans P., et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre,retrospective study of the Rare Cancer Network. Lancet Oncol 2006, 7:652-656.
39. Rakovitch E., Narod S.A., Nofech-Moses S., Hanna W., Thiruchelvam D., Saskin R., et al. Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis. Int J Radiat Oncol Biol Phys. 2013, 86:491-497.
40. Whelan T.J., Pignol J.P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362:513-520.
41. Group S.T., Bentzen S.M., Agrawal R.K., Aird E.G., Barrett J.M., Barrett-Lee P.J., et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008, 9:331-341.
42. Group S.T., Bentzen S.M., Agrawal R.K., Aird E.G., Barrett J.M., Barrett-Lee P.J., et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371:1098-1107.
43. Williamson D., Dinniwell R., Fung S., Pintilie M., Done S.J., Fyles A.W. Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ. Radiother Oncol 2010, 95:317-320.
44. Wai E.S., Lesperance M.L., Alexander C.S., Truong P.T., Culp M., Moccia P., et al. Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ. Cancer 2011, 117:54-62.
45. Roses R.E., Paulson E.C., Sharma A., Schueller J.E., Nisenbaum H., Weinstein S., et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:1386-1389.
46. Rakovitch E., Nofech-Mozes S., Hanna W., Narod S., Thiruchelvam D., Saskin R., et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2012, 106:1160-1165.
47. Solin L.J., Gray R., Baehner F.L., Butler S.M., Hughes L.L., Yoshizawa C., et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013, 105:701-710.